Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad A Bousman

Showing results (1-10 of 142) with videos related to

Pageof 15
Sort By:
The Lancet. Psychiatry|February 21, 2023
Pharmacogenomics-informed clozapine therapyChad A Bousman
The Lancet. Psychiatry|April 20, 2019
CYP2D6 testing to guide risperidone and aripiprazole therapyChad A Bousman
The Lancet. Psychiatry|May 3, 2016
Commercial pharmacogenetic-based decision-support tools in psychiatryChad A Bousman, Malcolm Hopwood
Preventing Chronic Disease|February 18, 2010
Family history of lung cancer and contemplation of smoking cessationChad A Bousman, Lisa Madlensky
Molecular Neuropsychiatry|May 14, 2020
Estimating the Potential Impact of <i>CYP2C19</i> and <i>CYP2D6</i> Genetic Testing on Protocol-Based Care for Depression in Canada and the United StatesMikayla Fan, Chad A Bousman
Pharmacy (Basel, Switzerland)|November 22, 2022
Experience, Knowledge, and Perceptions of Pharmacogenomics among Pharmacists and Nurse Practitioners in Alberta HospitalsMeagan Hayashi, Chad A Bousman
Pharmacopsychiatry|March 23, 2019
Commercial Pharmacogenetic Tests in Psychiatry: Do they Facilitate the Implementation of Pharmacogenetic Dosing Guidelines?Mikayla Fan, Chad A Bousman
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|January 30, 2020
"Black box" pharmacogenetic decision-support tools in psychiatryChad A Bousman, Harris A Eyre
The Pharmacogenomics Journal|May 26, 2018
Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support toolsChad A Bousman, Boadie W Dunlop
JAMA Psychiatry|September 1, 2018
Pharmacogenetics in Psychiatry: A Companion, Rather Than Competitor, to Protocol-Based CareChad A Bousman, Daniel J Müller
Pageof 15

Showing results (1-10 of 142) with videos related to

Sort By:
Pageof 15
The Lancet. Psychiatry|February 21, 2023
Pharmacogenomics-informed clozapine therapyChad A Bousman
The Lancet. Psychiatry|April 20, 2019
CYP2D6 testing to guide risperidone and aripiprazole therapyChad A Bousman
The Lancet. Psychiatry|May 3, 2016
Commercial pharmacogenetic-based decision-support tools in psychiatryChad A Bousman, Malcolm Hopwood
Preventing Chronic Disease|February 18, 2010
Family history of lung cancer and contemplation of smoking cessationChad A Bousman, Lisa Madlensky
Molecular Neuropsychiatry|May 14, 2020
Estimating the Potential Impact of <i>CYP2C19</i> and <i>CYP2D6</i> Genetic Testing on Protocol-Based Care for Depression in Canada and the United StatesMikayla Fan, Chad A Bousman
Pharmacy (Basel, Switzerland)|November 22, 2022
Experience, Knowledge, and Perceptions of Pharmacogenomics among Pharmacists and Nurse Practitioners in Alberta HospitalsMeagan Hayashi, Chad A Bousman
Pharmacopsychiatry|March 23, 2019
Commercial Pharmacogenetic Tests in Psychiatry: Do they Facilitate the Implementation of Pharmacogenetic Dosing Guidelines?Mikayla Fan, Chad A Bousman
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|January 30, 2020
"Black box" pharmacogenetic decision-support tools in psychiatryChad A Bousman, Harris A Eyre
The Pharmacogenomics Journal|May 26, 2018
Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support toolsChad A Bousman, Boadie W Dunlop
JAMA Psychiatry|September 1, 2018
Pharmacogenetics in Psychiatry: A Companion, Rather Than Competitor, to Protocol-Based CareChad A Bousman, Daniel J Müller
Pageof 15